Retatrutide TFA (C007B-416278)

Retatrutide (LY3437943) TFA is a triple agonist peptide of the Glukagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and Glukagon-like peptide-1 receptor (GLP-1R) . Retatrutide TFA inhibits for human GCGR , GIPR, and GLP-1Appearance:SolidIC50& Target:EC50 (for human): 5.79 (GCGR), 0.0643 (GIPR), 0.775 nM (GLP-1R) . EC50 (for mouse): 2.32 (GCGR), 0.191 (GIPR), 0.794 nM (GLP-1R) . Ki (for human): 5.6 (GCGR), 0.057 (GIPR), 7.2 nM (GLP-1) .In Vitro:Retatrutide (LY3437943) TFA has efficacy for human GCGR, GIPR, and GLP-1R with EC 50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide has efficacy for mouse GCGR, GIPR, and GLP-1R with EC 50 values of 2.32, 0.191 and 0.794 nM, respectivIn Vivo:Retatrutide (LY3437943) TFA (s.c.; 0.47mg/kg; single) engages GCGR in vivo and can improve glucose tolerance in an ipGTT through either the GIP or GLP-1 receptors. Retatrutide (s.c.; 10 mL/kg; cycle every 3 days; for 21 days) causes great body weighBiological Activity:Retatrutide (LY3437943) TFA is a triple agonist peptide of the Glukagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and Glukagon-like peptide-1 receptor (GLP-1R) . Retatrutide TFA inhibits for human GCGR , GIPR, and GLP-1.

Specifications and Purity: ≥97%

Molecular Formula: C221H342N46O68(free)

Molecular Weight: 4731.33(free)